Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT03520686. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 3, Open-Label, 4-Cohort Study of Nogapendekin Alfa Inbakicept in Combination With Current Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase 3, open-label, 4-cohort study (3 randomized cohorts and 1 single-arm cohort). Participants enrolled in each cohort will be treated as detailed below. Each study cohort will be analyzed separately. Treatment will continue for up to 2 years, or until the patient experiences confirmed progressive disease or unacceptable toxicity, withdraws consent, or if the investigator feels that it is no longer in the patient's best interest to continue treatment. Patients will be followed for disease progression, post-therapies, and survival through 24 months after the first dose of study drug.
Study identification
- NCT ID
- NCT03520686
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 102 participants
Conditions and interventions
Conditions
Interventions
- NAI + Pembrolizumab Drug
- NAI + Nivolumab + Ipilimumab Drug
- NAI + Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel Drug
- Cisplatin/Carboplatin + Pemetrexed + Pembrolizumab + NAI Drug
- Cisplatin/Carboplatin + Pemetrexed + Atezolizumab + NAI Drug
- Carboplatin + Paclitaxel + Atezolizumab + Bevacizumab + NAI Drug
- Carboplatin + Nab-paclitaxel + Atezolizumab + NAI Drug
- Pembrolizumab Drug
- Pembrolizumab + Carboplatin + Nab-paclitaxel or Paclitaxel Drug
- Drug: Cisplatin/Carboplatin and Pemetrexed plus Pembrolizumab Drug
- Cisplatin/Carboplatin and Pemetrexed plus Atezolizumab Drug
- Carboplatin and Paclitaxel plus Atezolizumab and Bevacizumab Drug
- Carboplatin and Nab-paclitaxel plus Atezolizumab Drug
- Nogapendekin alfa inbakicept (NAI) + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 18, 2018 (Actual)
- Primary completion
- Oct 13, 2025 (Actual)
- Completion
- Oct 13, 2025 (Actual)
- Last update posted
- May 26, 2026
2018 – 2025
United States locations
- U.S. sites
- 31
- U.S. states
- 18
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alaska Urological Institute - Alaska Clinical Research Center | Anchorage | Alaska | 99503 | — |
| Genesis Cancer Center | Hot Springs | Arkansas | 71913 | — |
| Chan Soon-Shiong Institute for Medicine | El Segundo | California | 90245 | — |
| Adventist Health Glendale | Glendale | California | 92106 | — |
| MemorialCare Health System | Long Beach | California | 90806 | — |
| Adventist Health White Memorial | Los Angeles | California | 90033 | — |
| Hoag Memorial Hospital | Newport Beach | California | 92663 | — |
| Desert Hematology Oncology Medical Group | Rancho Mirage | California | 92270 | — |
| Memorial Healthcare | Hollywood | Florida | 33021 | — |
| Baptist Health South Florida - Miami Cancer Institute | Miami | Florida | 33176 | — |
| Healthcare Research Network | Tinley Park | Illinois | 60487 | — |
| Baptist Health - Lexington | Lexington | Kentucky | 40503 | — |
| Baptist Health Louisville | Louisville | Kentucky | 40503 | — |
| Karmanos Cancer Center | Detroit | Michigan | 48201 | — |
| Mercy Research Joplin | Joplin | Missouri | 64804 | — |
| St. Vincent Frontier Cancer Center | Billings | Montana | 59102 | — |
| Astera Cancer Care | East Brunswick | New Jersey | 08816 | — |
| University of Rochester | Rochester | New York | 14642 | — |
| Stony Brooke Medicine | Stony Brook | New York | 11794 | — |
| Mercy Research Oklahoma City | Oklahoma City | Oklahoma | 73120 | — |
| LeHigh Valley | Allentown | Pennsylvania | 18103 | — |
| Gettysburg Cancer Center | Gettysburg | Pennsylvania | 17325 | — |
| Medical University of South Carolina (MUSC) - Hollings Cancer Center (HCC) | Charleston | South Carolina | 29425 | — |
| Saint Francis Cancer Center/Bon Secours St. Francis Health System | Greenville | South Carolina | 29607 | — |
| Avera Cancer Institute | Sioux Falls | South Dakota | 57105 | — |
| University of Tennessee Medical Center | Knoxville | Tennessee | 37920 | — |
| Baptist Cancer Center | Memphis | Tennessee | 38120 | — |
| Texas Oncology-Austin | Austin | Texas | 78745 | — |
| Texas Oncology-Bedford | Bedford | Texas | 76002 | — |
| Oncology Consultants, PA | Houston | Texas | 77030 | — |
| Bon Secours Richmond | Richmond | Virginia | 23114 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03520686, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 26, 2026 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03520686 live on ClinicalTrials.gov.